AccuStem Sciences, Inc.
ACUT
$0.276
-$0.0193-6.54%
Details
Health Care
Pharmaceuticals, Biotechnology and Life Sciences
3
Business Decription
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing products for the treatment and management of various cancers. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company was founded in 2013 and is headquartered in New York, New York.